Cargando…

Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer

ABSTRACT: The role of radiotherapy in advanced medullary thyroid carcinoma (MTC) is confined to patients in whom surgical treatment or the administration of tyrosine kinase inhibitors are not possible or contraindicated. High fractionated radiation doses during radiosurgery or fractionated stereotac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kukulska, Aleksandra, Krajewska, Jolanta, Kołosza, Zofia, Grządziel, Aleksandra, Gajek, Mateusz, Paliczka-Cieślik, Ewa, Syguła, Dorota, Ficek, Kornelia, Kluczewska-Gałka, Aneta, Jarząb, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353818/ https://www.ncbi.nlm.nih.gov/pubmed/34372848 http://dx.doi.org/10.1186/s12902-021-00832-4

Ejemplares similares

The role of postoperative adjuvant radiotherapy in local recurrence risk in medullary thyroid carcinoma
por: Kukulska, Aleksandra, et al.
Publicado: (2019)

Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer
por: Ledwon, Aleksandra, et al.
Publicado: (2021)

Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
por: Krajewska, Jolanta, et al.
Publicado: (2019)

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Lobo-isthmectomy in the management of differentiated thyroid cancer
por: Krajewska, Jolanta, et al.
Publicado: (2023)

13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2009)

Comparison of clinical examination with orbital MRI evaluation in patients with thyroid orbitopathy - do we need imaging and when?
por: Król, Aleksandra, et al.
Publicado: (2013)

Differences in Gene-Gene Interactions in Graves’ Disease Patients Stratified by Age of Onset
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2016)

Current status of the prognostic molecular markers in medullary thyroid carcinoma
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2020)

Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
por: Krajewska, Jolanta, et al.
Publicado: (2020)

Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?
por: Szpak-Ulczok, Sylwia, et al.
Publicado: (2020)

(131)I thyroid activity and committed dose assessment among family members of patients treated with radioactive iodine
por: Brudecki, K., et al.
Publicado: (2020)

Presentation of points of general discussion and voting among the speakers of the European Thyroid Association-Cancer Research Network (ETA-CRN) meeting in Lisbon, 2009, entitled ”European comments to ATA medullary thyroid cancer guidelines”
por: Jarząb, Barbara, et al.
Publicado: (2013)

TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2020)

Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients with Head and Neck Region Tumours
por: Polanowski, Paweł, et al.
Publicado: (2022)

Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of (1)H HR MAS NMR spectroscopy
por: Skorupa, Agnieszka, et al.
Publicado: (2021)

Stereotactic Radiotherapy in Combination with Immunotherapy in Treatment of Advanced Recurrent Squamous Cell Carcinoma of the Larynx
por: Polanowski, Paweł, et al.
Publicado: (2023)

Stereotactic Radiotherapy Boost in Treatment of Persistent Periocular Sebaceous Carcinoma after Surgery
por: Polanowski, Paweł, et al.
Publicado: (2023)

Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2014)

Association between Age at Diagnosis of Graves' Disease and Variants in Genes Involved in Immune Response
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2013)

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours
por: Wojtas, Bartosz, et al.
Publicado: (2017)

High-dose stereotactic radiotherapy boost in the treatment of squamous cell carcinoma of the head and neck region
por: Polanowski, Paweł, et al.
Publicado: (2022)

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
por: Kos-Kudła, Beata, et al.
Publicado: (2017)

Successful Treatment of Adenoid Cystic Carcinoma with the Application of a High-Dose Stereotactic Body Radiotherapy Boost
por: Polanowski, Paweł, et al.
Publicado: (2021)

Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Corrigendum: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping
por: Fujarewicz, Krzysztof, et al.
Publicado: (2007)

Copper transport system and response to ovarian cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Overall survival analysis of > 65-year-old patients with breast cancer based on their molecular, clinicopathological and laboratory factors
por: Huszno, Joanna, et al.
Publicado: (2022)

Histopathological Examination of an Explanted Heart in a Long-Term Responder to Cardiac Stereotactic Body Radiotherapy (STereotactic Arrhythmia Radioablation)
por: Miszczyk, Marcin, et al.
Publicado: (2022)

Introduction to European comments on “Medullary Thyroid Cancer: management guidelines of the American Thyroid Association”
por: Jarzab, Barbara, et al.
Publicado: (2013)

Outcome of COVID-19 infection in cancer patients during active systemic anticancer treatment. Single-institution experience. A retrospective analysis
por: Nowara, Elżbieta, et al.
Publicado: (2021)

Checkpoint Kinase 2 (CHEK2) Mutation in Renal Cell Carcinoma: A Single-Center Experience
por: Huszno, Joanna, et al.
Publicado: (2018)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms, efficiency and toxicity of cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Stereotactic Neurosurgical Treatment Options for Craniopharyngioma
por: Trippel, Michael, et al.
Publicado: (2012)

Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
por: Rusinek, Dagmara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k74174va32jo35p3r1pr7s83jv